Market Pulse
Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
Completed enrollment in Phase 2 Seabreeze STAT studies for asthma and COPD, with topline results expected in September 2026.
Read full analysis →
Q4 revenue hit $2.05B, up 34% YoY and 42% pro forma.
Read full analysis →
Longeveron anticipates September 2026 topline results from Phase 2b ELPIS II trial for laromestrocel in hypoplastic left heart syndrome (HLHS).
Read full analysis →
Completed the sale of its Movies business for $70 million in cash, enabling full repayment of $40.1 million in senior debt.
Read full analysis →
Acrivon expects interim Phase 2b data for ACR-368 in serous endometrial cancer by H2 2026
Read full analysis →
BioStem Technologies reported $7.9 million in revenue for Q2 2026, up 29% sequentially from Q1 2026.
Read full analysis →
BioCardia received positive regulatory feedback from Japan’s PMDA and the U.S. FDA on its CardiAMP Cell Therapy.
Read full analysis →
Stem's Q2 2026 revenue declined 12% YoY to $33.7M, driven by reduced battery hardware resales and lower managed services revenue.
Read full analysis →
Zealand Pharma sells royalty rights for rusfertide to Royalty Pharma for $100M.
Read full analysis →
SKYX reported Q2 2026 revenue of $25.3M, up 14% from Q1 2026 and 10% YoY.
Read full analysis →
RenovoRx reported $909,000 in Q2 2026 revenue, up 61% sequentially and 115% year-over-year.
Read full analysis →
Alto Neuroscience reported Q2 2026 financial results, highlighting progress in its ALTO-207 pipeline.
Read full analysis →
YARTEMLEA generated $32.2M in gross revenues in Q2 2026, up 190% from Q1.
Read full analysis →
$9.1 million in net product revenue for KOMZIFTI, up 57% from Q1 2026.
Read full analysis →
Pollard Banknote reported Q2 2026 revenue of $154.8 million, up 8.5% year-over-year.
Read full analysis →
Sangamo Therapeutics concluded a court-supervised auction, selling key assets for $163.55M in cash and up to $100M in milestones.
Read full analysis →
AEVEX to acquire BlackSea Technologies for up to $650M, including $250M in cash and $350M in stock.
Read full analysis →
STAAR Surgical reported Q2 2026 net sales of $93.5 million, up 111% year-over-year.
Read full analysis →
Net sales increased by 1.1% to $1.19 billion in Q2 2026, but comparable store sales declined by 0.3%.
Read full analysis →
Hyperion DeFi reported record $31M net income for Q2 2026, up from $8.8M in Q1 2026.
Read full analysis →
